

# South Australian Neonatal Medication Guidelines

# **multivitamins penta-vite**

## **infant 0-3 years oral liquid**

© Department of Health, Government of South Australia. All rights reserved

### **Note**

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

## **Dose and Indications**

**Neonates born < 34 weeks gestation or weighing < 2000g**

**Neonates with cholestasis**

**All neonates of mothers with known vitamin D deficiency**

**All neonates of mothers from at risk groups\***

**Oral**

0.45mL daily once tolerating full enteral feeds

**ISBN number:**  
**Endorsed by:**  
**Last Revised:**  
**Contact:**

978-1-74243-543-5  
South Australian Maternal & Neonatal Clinical Network  
18/07/2013  
South Australian Neonatal Medication Guidelines Workgroup at:  
NeoMed@health.sa.gov.au

## Preparation and Administration

### Oral

Each 0.45mL dose contains:

Vitamin A (retinyl palmitate)	490 micrograms
Vitamin B1 (thiamine hydrochloride)	540 micrograms
Vitamin B2 (riboflavine sodium phosphate)	1.1mg (equivalent to riboflavin 800 micrograms)
Vitamin B3 (nicotinamide)	7.1 mg
Vitamin B6 (pyridoxine hydrochloride)	135 micrograms
Vitamin C (ascorbic acid)	42.8 mg
Vitamin D3 (cholecalciferol)	10.1 micrograms

To be stored in the refrigerator after opened. Use within 9 weeks of opening.

## Adverse Effects

Not expected with therapeutic dose

## Practice Points

- > Continue therapy for 6 months corrected age, or when treating neonates with cholestasis until conjugated bilirubin normalises
- > \*Neonates from at risk groups include those of veiled/dark skinned mothers, mothers who are housebound for any reason or who are recently arrived refugees
  - For at risk groups continue treatment until infant is 12 months of age

## Version control and change history

**PDS reference:** OCE use only

Version	Date from	Date to	Amendment
1.0	July 2013	current	Original version

**ISBN number:**  
**Endorsed by:**  
**Last Revised:**  
**Contact:**

978-1-74243-543-5  
South Australian Maternal & Neonatal Clinical Network  
18/07/2013  
South Australian Neonatal Medication Guidelines Workgroup at:  
NeoMed@health.sa.gov.au